Massachusetts General Hospital
The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational \[drug/device/intervention\] to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has approved sonrotoclax for the treatment of patients with mantle cell lymphoma. However, the U.S. FDA has not approved sonrotoclax for the treatment of patients with CLL/SLL. The U.S. FDA has approved zanubrutinib and obinutuzumab as a treatment option for CLL/SLL. The U…
Inclusion Criteria: * Participant must have CLL or SLL (WHO criteria). * Participant must require treatment according to iwCLL guidelines. * Participants must have no prior systemic therapy for CLL or SLL, except: * Prior local radiation for symptomatic disease is permitted. * Short course systemic corticosteroids is permissible for disease control, improvement of performance status, or non-cancer indication. However, duration of steroid course must be ≤14 days with maximum daily dose of ≤100 mg prednisone, ≤20 mg dexamethasone, or equivalent, and must be discontinued prior to study trea…
Bruton's Tyrosine Kinase (BTK) inhibitor
B-cell lymphoma 2 (BCL2) protein inhibitor
Anti-CD20 monoclonal antibody
Bruton's Tyrosine Kinase (BTK) degrader
Arctuva estimate
Verify or correct the compensation shown for this listing.